Overview of Polypharmacy and Drug Interactions in Chronic Kidney Disease Patients at Siloam Hospitals Lippo Village
Abstract
Patients diagnosed with CKD in Indonesia have increased from 2% in 2013 to 3.8% in 2018. Polypharmacy is commonly found in CKD patients, especially in CKD patients with comorbidities. CKD with comorbidities will make the treatment more complex and expensive. This study was conducted to assess the relationship between polypharmacy and drug interactions in CKD patients. Data analysis was carried out descriptively on CKD patients at "X" Hospital in the period October to December 2022 and data were displayed in the form of tables and graphs. The results showed that the majority of patients with chronic kidney disease (CKD) were aged 46-65 years with 42 patients (50.0%). Chronic kidney disease (CKD) patients who get prescriptions for more than 5 drugs are 80 (95.2%) patients. Comorbidities that often occur in chronic kidney disease (CKD) patients are hypertension with 62 (19.62%) patients, diabetes mellitus with 29 (9.18%) patients, and coronary heart disease with 27 (8.54%) patients. From 84 patients, there were 626 potential drug interactions including 152 (24.28%) drug interactions with minor severity, 434 (69.33%) drug interactions with moderate severity, and 40 (6.39%) drug interactions with major severity. CKD patients who have one or more comorbidities will increase the risk of polypharmacy and an increased risk of drug interactions.
References
Riskesdas. (2018). Laporan Riskesdas 2018 Nasional.pdf. In Lembaga Penerbit Balitbangkes (p.674).
Agustin, O. A., & Fitrianingsih, F. (2021). Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan Di Apotek X Jambi. Electronic Journal Scientific of Environmental Health And Disease, 1(1), 1–10. https://doi.org/10.22437/esehad.v1i1. 10759Cascorbi, I. (2012).
Arzneimittelinteraktionen: Prinzipien, Beispiele und klinische Folgen. Deutsches Arzteblatt International, 109(33–34), 546–556. https://doi.org/10.3238/arztebl.2012.0 546
Cepeda, O. A., & Morley, J. E. (2012). Polypharmacy. Pathy’s Principles and Practice of Geriatric Medicine: Fifth Edition, 1(1), 145–152. https://doi.org/10.1002/97811199529 30.ch13
Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 12(1), 7–11. https://doi.org/10.1016/j.kisu.2021.11. 003
MacRae, C., Mercer, S. W., Guthrie, B., & Henderson, D. (2021). Comorbidity inchronic kidney disease: A large
crosssectional study of prevalence in Scottish primary care. British Journal of General Practice, 71(704), E243–
E249. https://doi.org/10.3399/bjgp20X714125
Okunade, K. (2018). Profiles of Sugar Fermenting Bacteria of the Oral Cavity among Children with Dental Caries Attending Stomatology Services at Ruhengeri Referral Hospital in Musanze District, Northern Rwanda. January, 19–26. https://doi.org/10.4103/npmj.npmj
Shahzadi, A., Sonmez, I., Kose, C., Oktan, B., Alagoz, S., Sonmez, H., Hussain, A., & Akkan, A. G. (2022). The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa
Nephrology Unit. Medicina (Lithuania), 58(2), 1–10. https://doi.org/10.3390/medicina58020183
Sleem A., Masood I., K. T. M. (2017). Clinical relevancy and determinants of potential drug – drug interactions in chronic kidney disease patients : results from a retrospective analysis. 71–77.
1.png){kind=small}
